Effect of Raloxifene on Cardiovascular Adverse Events in Postmenopausal Women With Osteoporosis
Authors:
- Kristine EnsrudKEKristine Ensrud
- Mary Jane GeigerMGMary Jane Geiger
- 1 February 2006
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 97 (4) , 520-527
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Safety assessment of raloxifene over eight years in a clinical trial settingCurrent Medical Research and Opinion, 2005
- Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of RaloxifeneJNCI: Journal of the National Cancer Institute, 2004
- Risk of ischemic stroke with tamoxifen treatment for breast cancerNeurology, 2004
- Cardiovascular effects of raloxifene: the arterial and venous systemsAmerican Heart Journal, 2004
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Meta-analysis of vascular and neoplastic events associated with tamoxifenJournal of General Internal Medicine, 2003
- Estrogen plus Progestin and the Risk of Coronary Heart DiseaseNew England Journal of Medicine, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal WomenJAMA, 2002
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999